The company has a strong research and development base that allows it to create completely new classes of effective medicines. During the last 5 years, Celon has delivered 6 successful data readouts, initiated 11 clinical trials, and raised capital through EU-funded financings and public offerings.
Cyborg Score Rationale
Celon demonstrates solid R&D capabilities and recent clinical progress, but faces profitability challenges with negative EPS (-$0.59) and modest revenue ($48.9M). The company's small market cap ($348M) and sub-$7 stock price reflect investor caution, though its public market access and European regulatory credentials provide a foundation.
Top Insights
Strong R&D foundation with 60+ scientists including PhD-level researchers focused on innovative drug development
Recent recognition as Diamonds of Innovation 2025 laureate demonstrates competitive standing in pharmaceutical sector
Currently unprofitable despite active clinical pipeline, indicating capital-intensive growth phase requiring continued funding
Recent clinical progress (6 data readouts, 11 trials initiated in past 5 years) suggests pipeline advancement toward commercialization
Named Competitors
Generic Pharmaceuticals — Global generic and specialty pharma manufacturer